Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 238 publications
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 19, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.
Journal: Cancer discovery
Published: October 07, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Journal: Nature medicine
Published: March 15, 2025
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 13, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2024
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: October 18, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 20, 2024
Renal Neoplasms with Concurrent Castleman-Like Regional Lymphadenopathy.
Journal: International journal of surgical pathology
Published: August 30, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Journal: The British journal of dermatology
Published: July 30, 2024
Last Updated: 09/26/2026